ONCOCROSS

  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

CONTACT US
  • KR
  • EN
  • Company

    • Mission

    • About Us

    • History

    • Leadership

    • Scientific Advisory Board

  • Business Areas

    • Neo Omics

    • DBB

    • Early Cancer Detection & Monitoring

    • Collaboration

  • Technology Platform

    • RAPTOR AI® VERSION 2.0

    • ONCOfind AI ®

  • Pipeline

  • News/IR

    • Notice

    • Press Releases

    • IR Materials

    • Knowledge Hub

    • Latest Cancer Information

    • Disclosure Information

    • Stock Information

  • OncoMaster

  • KR
  • EN
CONTACT US
  • Main
  • News/IR
  • Press Releases

医药网

Oncocross与DaeWoong制药签署共同研发协议并获得战略融资

  • 06-02-2021
http://news.pharmnet.com.cn/news/2021/06/02/555181.html
Previous
온코크로스, RNA 발현 패턴 기반으로 최적의 신약·질환 조합 탐색 07-09-2021
Next
AI新药研发公司(株)Oncocross与DaeWoong制药签署共同研发协议并获得战略融资 05-26-2021
List

Please enter a prompt

ONCOCROSS
CEO
Yi Rang KIM / Jihoon KANG
Address
Room 905, 7 Beobwon-ro 11-gil, Songpa-gu, Seoul, Korea (Munjeong-dong, Munjeong Hyundai Knowledge Industry Center 1-2)
Tel
02-717-9967
Fax
02-867-9968
Email
oncocross@oncocross.com
Terms & Conditions Privacy Policy Cookie Policy
ⓒ ONCOCROSS CO., LTD. All Rights Reserved.